What are the contraindications for Epoetin (Erythropoietin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

From the Guidelines

Epoetin is contraindicated in patients with uncontrolled hypertension, known hypersensitivity to epoetin or its components, pure red cell aplasia (PRCA) that developed following treatment with any erythropoietin protein drugs, and certain malignancies where the goal is cure, particularly when treating anemia in cancer patients not receiving concurrent chemotherapy. According to the most recent evidence 1, epoetin should not be used in treatment of anemia associated with malignancy in patients who are not receiving concurrent myelosuppressive chemotherapy, with the exception of patients with lower risk myelodysplastic syndrome to avoid transfusions.

Key Contraindications

  • Uncontrolled hypertension
  • Known hypersensitivity to epoetin or its components
  • Pure red cell aplasia (PRCA) that developed following treatment with any erythropoietin protein drugs
  • Certain malignancies where the goal is cure, particularly when treating anemia in cancer patients not receiving concurrent chemotherapy

Important Considerations

  • Epoetin carries a boxed warning regarding increased risk of death, serious cardiovascular events, stroke, and thromboembolism when administered to target hemoglobin levels greater than 11 g/dL
  • Caution is warranted in patients with seizure disorders, thrombotic vascular disease, or those undergoing surgery, as epoetin may increase complications in these populations
  • Regular monitoring of blood pressure, hemoglobin levels, and iron status is essential during treatment to minimize risks, as recommended by 1.

Additional Contraindications

  • Hemoglobinopathies, such as sickle cell disease, may respond poorly to epoetin therapy, as noted in 2
  • Folate and vitamin B12 deficiency can affect the response to epoetin, and investigation of cofactor adequacy is necessary in cases of loss of responsiveness to epoetin, as mentioned in 2
  • Multiple myeloma, malnutrition, and hemolysis are also conditions that may affect the response to epoetin, as discussed in 2

From the FDA Drug Label

Uncontrolled hypertension Pure red cell aplasia (PRCA) that begins after treatment with Epogen or other erythropoietin protein drugs Serious allergic reactions to Epogen Use of the multiple-dose vials containing benzyl alcohol in neonates, infants, pregnant women, and lactating women

The contraindications for epocrit (epoetin) are:

  • Uncontrolled hypertension
  • Pure red cell aplasia (PRCA) that begins after treatment with epoetin or other erythropoietin protein drugs
  • Serious allergic reactions to epoetin
  • Use of the multiple-dose vials containing benzyl alcohol in:
    • Neonates
    • Infants
    • Pregnant women
    • Lactating women 3 3

From the Research

Contraindications for Epoetin (Erythropoietin)

The following are potential contraindications for epoetin (erythropoietin) therapy:

  • Hypertension: Epoetin therapy has been associated with increased blood pressure and hypertension in some patients 4, 5, 6.
  • Cardiovascular disease: Patients with pre-existing cardiovascular disease may be at increased risk of cardiovascular events, such as heart attacks and strokes, when treated with epoetin 7, 8.
  • Chronic kidney disease: While epoetin is often used to treat anemia in patients with chronic kidney disease, it may also increase the risk of cardiovascular events and mortality in these patients 7, 5.
  • High blood pressure: Patients with uncontrolled high blood pressure may be at increased risk of cardiovascular events when treated with epoetin 4, 6.
  • Diabetes: Patients with diabetes may be at increased risk of cardiovascular events and mortality when treated with epoetin 7.

Special Considerations

  • Patients receiving dialysis: These patients may be at increased risk of cardiovascular events and mortality when treated with epoetin 7.
  • Patients with concurrent diabetes or high blood pressure: These patients may be at increased risk of cardiovascular events and mortality when treated with epoetin 7.
  • Resistance to erythropoiesis-stimulating agents: Some patients may develop resistance to epoetin therapy, which can increase the risk of cardiovascular events and mortality 7.

References

5
Research

Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018

6
Research

Prevention of erythropoietin-associated hypertension.

Hypertension (Dallas, Tex. : 1979), 2007

8
Research

Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects.

Current drug targets. Cardiovascular & haematological disorders, 2005

Related Questions

Which of the following is NOT a cause of resistant hypertension: cyclosporine, nonsteroidal anti-inflammatory drugs (NSAIDs), poor compliance with antihypertensive therapy, erythropoietin, or dietary potassium intake?
Can a patient with end‑stage renal disease (CKD V) and anemia (high reticulocyte count, elevated ferritin, transferrin saturation 37 %) safely consume calamansi (calamondin)?
What is the recommended GI workup for a patient with chronic anemia and Chronic Kidney Disease (CKD)?
What is the target hemoglobin (Hb) level for a patient with congestive heart failure (CHF)?
What dosing regimen should be followed for erythropoietin when the hemoglobin reaches 12.8 g/dL and blood pressure is 152/92 mmHg, and when should the dose be reduced?
What is the induction plan for anesthesia in a patient with severely reduced Ejection Fraction (EF) and severe aortic stenosis?
Can Latuda (lurasidone) cause thrombocytopenia?
What type of anemia is characterized by low iron (34) levels, elevated iron binding capacity (224), low iron saturation (15%), and normal ferritin (256) levels?
What should be added to the treatment regimen of a 68-year-old African American male with hypertension, currently on lisinopril (angiotensin-converting enzyme inhibitor) 20mg?
What are the next steps for an 86-year-old female with a partially delayed nephrogram, moderate to severe right hydroureteronephrosis, and a large pelvic mass possibly arising from the right ovary, measuring 5.2 x 4.0 x 6.1 cm?
Is a right ventricular systolic pressure (RVSP) of 35 mmHg concerning?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.